June 26, 2020, HOUSTON — Celltex, a Houston, Texas-based biotechnology company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). [Read more…]
Orca Bio Raises $192M Series D to Develop High Precision Allogenic Cell Therapies
Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders
High precision cell therapies manufactured by Orca Bio have the potential to replace conventional bone marrow transplants and expand the eligible patient population
5 Questions to Ask Your Doctor About Stem Cell Transplants
Stem cell transplants are used to treat certain types of cancer as well as some other conditions. Stem cell transplants have even completely eradicated HIV in some patients.
If you are considering stem cell transplants for your health issues, you will understandably have a lot of questions.
Knowing the right questions to ask about this complex procedure isn’t always that easy, however. We’re here to help with that.
Read on as we look at five important questions to ask your doctor about stem cell transplants. [Read more…]
Cynata to Launch World’s First Phase 3 Trial with an iPSC-Derived Cell Therapeutic
With an anticipated enrollment of 440 patients, it will be the world’s largest trial ever completed with an iPSC-derived cell therapeutic.
It’s official. Australian stem cell company Cynata Therapeutics is preparing to test its iPSC-derived cell therapeutic, CYP 004, in a Phase 3 clinical trial enrolling up to 440 patients. Led by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC), the historic trial will assess whether Cynata’s cell therapeutic, CYP-004, has the capacity to improve patient outcomes in osteoarthritis (OA).
CYP-004 is an allogeneic, iPSC-derived mesenchymal stem cell (MSC) product derived using Cynata’s proprietary Cymerus™ technology. The clinical trial is set to achieve two world-firsts:
- It will be the world’s first clinical trial involving an iPSC-derived cell therapeutic product to enter Phase 3.
- It will be the largest trial ever completed with an iPSC-derived cell therapeutic, with an anticipated enrollment of 440 patients.
Funding for COVID-19 Countermeasures: Diagnostics, Vaccines, Treatments
COVID-19 is a global emergency of unprecedented scale. Affecting all 7.2 billion people worldwide, it is largest pandemic in modern history. Because it could take a year or two before vaccines get approved, manufactured at high volume, and distributed on a global scale, there’s a dire need for treatments to reduce the mortality rate of the coronavirus while we wait. To this end, agencies around the world have been rapidly announcing funding support for the development of diagnostics, vaccines and therapeutics against COVID-19. [Read more…]
- « Previous Page
- 1
- …
- 185
- 186
- 187
- 188
- 189
- …
- 334
- Next Page »